China NMPA Drug Inspection - Mianyang Shenlong Pharmaceutical Co., Ltd. - Pyrrosia

The Sichuan Provincial Food and Drug Administration (NMPA) issued an announcement on April 13, 2018, detailing the "First Issue of 2018" provincial drug quality announcement. This followed a series of key variety and routine supervision sampling inspections conducted by city and prefecture-level food and drug administrations across drug production, operation, and use units in Sichuan Province. The inspections, initiated under the 2018 Provincial Drug Sampling Inspection Task, identified 26 batches of substandard drugs from various manufacturers and sources, including Zhejiang Dongri Pharmaceutical Co., Ltd., Jilin Province Overseas Chinese Pharmaceutical Group, and several Sichuan-based pharmaceutical and traditional Chinese medicine companies. Main violations centered on quality control failures, with drugs found non-compliant with National Food and Drug Administration Standards or the Chinese Pharmacopoeia. Specific issues included discrepancies in appearance, content determination (e.g., baicalin, narcissin, atractylodes lancea, epimedium), properties, and various impurities (e.g., acid-insoluble ash, total ash, moisture, heavy metals, drug residue). Packaging weight differences and identification issues were also noted. The regulatory framework for these actions is the "Drug Administration Law of the People's Republic of China," specifically Articles 73, 74, and 75. Local food and drug administrations are required to investigate the illegal activities of the involved enterprises, publicly disclose the investigation results within three months, and report findings to the provincial bureau. This initiative aims to strengthen drug supervision and ensure drug safety and effectiveness for the public.